Sino Biopharmaceutical Limited continued to improve its ESG governance structure. With the Board as the responsible, decision-making and supervisory body for ESG, we have established the board-level Environment, Social and Governance (ESG) committee, to oversee major ESG-related issues of the Group and to advise the Board on ESG risks, opportunities, policies and actions. At the management level, the Group has established an ESG Work Management Committee with the Group’ s senior management acting as the standing committee members, and the persons in charge of the Group’s ESG-related functions and certain major member companies as the committee members. They are responsible for continuously improving the internal supervision of ESG risks, organizing the implementation of the Board ‘s ESG strategies and requirements, reviewing ESG risks and opportunities in a timely manner based on factors such as the macro environment and business changes, and regularly reviewing the annual ESG work report and ESG-related information disclosure. In order to facilitate the implementation of ESG management work, the Group has also established the Office for ESG Department and ESG Work Management Committee, a dedicated ESG management department responsible for the overall planning, coordinating, organizing and promoting the execution of ESG tasks. The Group has formulated the “Regulations of the Sino Biopharmaceutical ESG Work Management Committee” and “Sino Biopharmaceutical Sustainable Management System” to regulate the relevant responsibilities and working mechanisms of the above ESG governance structure.

​